All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
DNAM-1 (DNAX Accessory Molecule-1) also known as CD226 (Cluster of Differentiation 226) or PTA1, is a ~65 kDa glycoprotein expressed on the surface of natural killer cells, platelets, monocytes and a subset of T cells. DNAX accessory molecule-1 (DNAM-1), plays an important role in the NK cell-mediated recognition and killing of Multiple myeloma cells. Tumor cells can express DNAX-1 ligands. Recently, scientists have identified the poliovirus receptor (PVR) CD155 and its family member CD112 (PVRrelated family 2 [PRR-2], also called as nectin-2), as the ligands for human DNAM-1. Although the human DNAM-1 ligands CD112 and CD155 are broadly distributed on epithelial and endothelial cells in many tissues, they are overexpressed on certain human tumors, including colorectal carcinomas, myeloid leukemias,14 and neuroblastomas, suggesting that the expression of DNAM-1 ligands is inducible by "stress" such as transformation and infection.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-MZ224 | Anti-DNAM-1 ligands, DNAM-1 h(CD3ζ) CAR, pCDCAR1 | Murine | DNAM-1-CD3ζ | Lentiviral | T cell | ||||
CAR-MZ225 | Anti-DNAM-1 ligands, DNAM-1 h(CD28-CD3ζ) CAR, pCDCAR1 | Murine | DNAM-1-CD28-CD3ζ | Lentiviral | T cell | ||||
CAR-MZ226 | Anti-DNAM-1 ligands, DNAM-1 h(OX40-CD3ζ) CAR, pCDCAR1 | Murine | DNAM-1-OX40-CD3ζ | Lentiviral | T cell | ||||
CAR-MZ227 | Anti-DNAM-1 ligands, DNAM-1 h(41BB-CD3ζ) CAR, pCDCAR1 | Murine | DNAM-1-41BB-CD3ζ | Lentiviral | T cell | ||||
CAR-MZ228 | Anti-DNAM-1 ligands, DNAM-1 h(CD28TM-CD28-CD3ζ) CAR, pCDCAR1 | Murine | DNAM-1-CD28TM-CD28-CD3ζ | Lentiviral | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION